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Abstract: Mesenchymal stem cells (MSCs) are undifferentiated cells with an unlimited 
capacity for self-renewal and able to differentiate towards specific lineages under 
appropriate conditions. MSCs are, a priori, a good target for cell therapy and clinical trials 
as an alternative to embryonic stem cells, avoiding ethical problems and the chance for 
malignant transformation in the host. However, regarding MSCs, several biological 
implications must be solved before their application in cell therapy, such as safe ex vivo 
expansion and manipulation to obtain an extensive cell quantity amplification number for 
use in the host without risk accumulation of genetic and epigenetic abnormalities. Cell 
surface markers for direct characterization of MSCs remain unknown, and the precise 
molecular mechanisms whereby growth factors stimulate their differentiation are still 
missing. In the last decade, quantitative proteomics has emerged as a promising set of 
techniques to address these questions, the answers to which will determine whether MSCs 
retain their potential for use in cell therapy. Proteomics provides tools to globally analyze 
cellular activity at the protein level. This proteomic profiling allows the elucidation of 
connections between broad cellular pathways and molecules that were previously 
impossible to determine using only traditional biochemical analysis. However; thus far, the 
results obtained must be orthogonally validated with other approaches. This review will 
OPEN ACCESS 
Proteomes 2014, 2 54 
 
focus on how these techniques have been applied in the evaluation of MSCs for their future 
applications in safe therapies. 
Keywords: mesenchymal stem cell; proteomic analysis; characterization; differentiation  
 
Abbreviations:  
DIGE difference in-gel electrophoresis 
2D-PAGE two-dimensional polyacrylamide gel electrophoresis 
ESI electrospray ionization 
GELFREE gel-eluted liquid fraction entrapment electrophoresis 
IEF iso-electric focusing 
IMAC immobilized metal ion affinity chromatography 
iTRAQ isobaric tags for relative and absolute quantification 
LC liquid chromatography 
LCM laser capture micro-dissection 
MALDI-MSI matrix-assisted laser desorption ionization mass spectrometry imaging 
MSCs mesenchymal stem cells 
18O (18)O-labeling of reactive carbonyl modifications 
PCR polymerase chain reaction 
PMF peptide mass fingerprinting 
SELDI-TOF-MS surface enhanced laser desorption/ionization-time of flight-mass spectrometry 
SCX strong cation exchange 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SID stable isotope dilution 
SILAC stable isotope labeling by/with amino acids in cell culture 
Ti20 tolerable intake 20 
1. Introduction  
Mesenchymal stem cells (MSCs) are multipotent cells with an important potential in human 
regenerative medicine because of their ability to migrate to sites of injury [1], their capability of 
suppressing the immune response [2] and their accessibility in large numbers from the patient’s own 
bone marrow or fat tissue. It has been increasingly observed that the transplanted MSCs do not 
necessarily engraft and differentiate at the site of injury, but might exert their therapeutic effects 
through secreted trophic signals [3]. MSCs secrete a variety of autocrine/paracrine factors that make 
up the secretome, which supports regenerative processes in the damaged tissue, induces angiogenesis, 
protects cells from apoptotic cell death and modulates the immune system. The MSC secretome has 
become a subject of intensive proteomic profiling in the search for and identification of released 
factors and microvesicles that might be applicable in regenerative medicine. Jointly with the methods 
for MSC isolation, expansion and differentiation, proteomic secretome analysis of MSC has been 
increased in use, mainly due to the extensive development of protein separation techniques and mass 
spectrometry, recently reviewed by Skalnikova et al. [4]. This review will focus on the study of the 
intracellular proteome. 
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The term proteomics encompasses all research methodologies aimed at qualitative and quantitative 
study of the proteins, or proteome, present in a cell type, tissue or organism at a given stage of 
development [5]. In the last decade, there has been an exponential increase in the use of these 
techniques in translational research, due in large part to the progress in state-of-the-art mass 
spectrometry. With this technique, developed in the middle of the last century [6], it is possible to 
calculate, with remarkable accuracy, the mass/charge ratio of any compound that can ionize, as well as 
the mass/charge ratio of the fragments originated by the collision of the compound with an inert gas. 
The accuracy in the measurement is so high that it is actually possible to identify the compound. In the 
case of proteomics, mass spectrometers are designed to identify and quantify peptides and proteins in a 
very sensitive and high-throughput manner. It has been widely accepted that proteomics can never 
replace, but complements, genomic information [7,8]. First, unlike what happens in genomics, 
proteomics studies lack a technique, such as polymerase chain reaction (PCR), to amplify these very 
low abundance molecules for study. This greatly complicates the study of very scarce proteins, such as 
growth factors or cytokines [9]. Unfortunately, the wide dynamic range of protein concentration causes 
the most abundant signal to mask the signal of low-abundance molecules. Finally, post-translational 
modifications, such as phosphorylation, glycosylation, etc., can completely change the function of a 
protein, but the total amount thereof does not vary. Due, at least in part, to these limitations, it is now 
required that the data obtained in individual samples be tested using proteomic techniques, including 
Western blot or enzyme-linked immuno sorbent assay (ELISA) or even genomic techniques, such as 
real-time PCR (RT-PCR).  
The protein expression profile of MSCs may reveal potential hazards associated with senescence 
and tumoral transformation that may occur during culture. Proteomic is a valuable tool for human 
MSC characterization following physiological modifications of the phenotypes of MSCs and 
identification of possible changes occurring during expansion. Mass spectrometry-based comparative 
membrane proteomics can enable the identification of novel cancer biomarkers by distinguishing 
proteins that change membrane localization between normal and malignant tissues and cells. The 
combination of analyzers and other types of available components has led in recent years to a long list 
of devices designed specifically for each type of molecule. Specifically, the range of platforms 
designed for the analysis of peptides and proteins has been adapted specifically to different qualitative 
and quantitative techniques (Table 1). This review describes proteomic techniques currently applied or 
prospectively applicable to MSC studies.  
Table 1. Studies of mesenchymal stem cells (MSCs) using quantitative proteomic techniques. 
Proteomic Technique MSC Source 
Biological 
significance 
Instrument Ref. 
2D-LC-MS/MS Bone marrow Characterization Q-TOF [10] 
2DE-MALDI-TOF/TOF MS Umbilical cord blood Characterization MALDI-TOF/TOF [11] 
2DE-MALDI-TOF-MS Amniotic fluid Characterization MALDI-TOF [12] 
2D-LC-MALDI-MS Bone marrow Characterization MALDI-TOF [13] 
2DE and combined MS and MS/MS Bone marrow Characterization MALDI-TOF/TOF [14] 
2DE and combined MS and MS/MS Umbilical cord Characterization MALDI-TOF/TOF [14] 
2DE and combined MS and MS/MS Placenta Characterization MALDI-TOF/TOF [14] 
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Table 1. Cont. 
Proteomic Technique MSC Source 
Biological 
significance 
Instrument Ref. 
DIGE-MALDI-TOF/TOF Bone marrow Characterization MALDI-TOF/TOF [15] 
2DE-PMF Bone marrow Characterization MALDI-TOF/TOF [16] 
2DE-PMF Bone marrow Characterization MALDI-TOF/TOF [17] 
GELFREE-LC-MALDI-TOF/TOF Bone marrow Characterization MALDI-TOF/TOF [18] 
2DE-MALDI-TOF-MS Bone marrow Extension culture MALDI-TOF [19] 
2DE-MALDI-TOF-MS Bone marrow Extension culture MALDI-TOF [20] 
2DE-MALDI-TOF-MS/MS Bone marrow Extension culture MALDI-TOF [21] 
2DE-MALDI-TOF-MS/MS Bone marrow Extension culture MALDI-TOF [22] 
SELDI-TOF-MS Adipose tissue Extension culture SELDI-TOF [23] 
2DE coupled MS Bone marrow Extension culture Q-TOF [24] 
2DE-MALDI-MS Bone marrow Senescence MALDI-TOF [25] 
2DE-ESI-Q-TOF-MS/MS Bone marrow Senescence Q-TOF [26] 
DIGE-MALDI-TOF-MS Bone marrow Extension culture MALDI-TOF [27] 
2DE-ESI-MS/MS Bone marrow Differentiation Q-TOF [28] 
LC-MS/MS Bone marrow Differentiation Q-TOF [29] 
DIGE-MALDI-TOF-MS Bone marrow Differentiation MALDI-TOF [30] 
2DE-MALDI-TOF-MS Bone marrow Differentiation MALDI-TOF [31] 
2DE-ESI-Q-TOF-MS/MS Umbilical cord blood Differentiation Q-TOF [32] 
DIGE-MALDI-TOF/TOF-MS/MS Adipose tissue Differentiation MALDI-TOF/TOF [33] 
2DE-MALDI-TOF/MS Umbilical cord blood Differentiation MALDI-TOF [34] 
LC-coupled MS/MS Intervertebral disc Differentiation LTQ [35] 
LC-coupled MS/MS Bone marrow Differentiation LTQ-Orbitrap [36] 
DIGE- MALDI-TOF/TOF-MS/MS Umbilical cord stroma Differentiation MALDI-TOF [37] 
SILAC-LC-MALDI-TOF/TOF-MS/MS Bone marrow Differentiation MALDI-TOF/TOF [38] 
DIGE-MALDI-TOF-MS Bone marrow Differentiation MALDI-TOF [39] 
SILAC-LC-MS/MS Bone marrow Differentiation LTQ-Orbitrap [40] 
DIGE-IEF-MALDI-MS/MS Bone marrow Cell Therapy MALDI-TOF/TOF [41] 
2DE-MALDI-TOF-MS Bone marrow Cell Therapy MALDI-TOF [42] 
DIGE-MALDI-TOF/TOF-MS/MS Bone marrow Cell Therapy MALDI-TOF/TOF [43] 
SDS-PAGE-LC coupled MS/MS Bone marrow Cell Therapy LTQ [44] 
LC-coupled MS/MS Bone marrow Cell Therapy LTQ-Orbitrap [36] 
DIGE-MALDI-TOF-MS Bone marrow Cell Therapy MALDI-TOF [45] 
2DE, two-dimensional electrophoresis; MALDI, matrix-assisted laser desorption ionization; TOF, time of 
flight; PMF, peptide mass fingerprinting; DIGE, difference in-gel electrophoresis; SELDI, surface enhanced 
laser desorption/ionization; ESI, electrospray ionization; SILAC, stable isotope labeling by/with amino  
acids in cell culture; IEF, iso-electric focusing; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel  
electrophoresis; LTQ, linear trap quadrupole. 
2. Proteomic Techniques 
Proteins extracts coming from cultured cells are highly complex protein samples that present a wide 
dynamic range of concentrations [46]. Fractionation of the sample is therefore necessary to reduce its 
complexity. Protein quantification performed by colorimetric or fluorometric assays is one of the 
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weaknesses of the entire proteome flow, because there is currently no universal method to quantify any 
sample with high accuracy and reproducibility. After fractionation by electrophoretic techniques, 
isoelectric focusing or chromatographic analysis, subsequent identification and quantification of the 
peptides allows the identification and quantification of the original proteins using certain algorithms. 
In some cases, directed digestion is initially performed in solution, followed by peptide fractionation as 
liquid chromatography (LC), strong cation exchange (SCX) or the off-gel separation of peptides. 
Alternatively, fractionation of proteins by gel size or isoelectric point is performed first as sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), two-dimensional polyacrylamide gel 
electrophoresis (2D-PAGE) or isoelectric focusing (IEF) followed by digestion. Sometimes, the 
digestion is performed between two successive fractionations, depending on the sample type and 
complexity. In any case, fractionation of the studied sample clearly decreases the complexity of the 
resulting fractions, but also lengthens the total time for analysis. 
It is currently accepted that a research project based on proteomics should have two phases. In the 
initial phase of shaping or profiling, the proteome or protein profile of a particular type of sample, such 
as a cell line or tissue samples at a given stage of development of MSCs, is determined. One way to do 
this is by two-dimensional electrophoresis (2DE) with subsequent identification of proteins by peptide 
mass fingerprinting using a matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) 
platform. In this technique, developed in the early nineteen-nineties by Henzel et al. [47], proteins are 
separated on acrylamide gels in two dimensions, by isoelectric point and by size and can be identified 
by the pattern of tryptic peptides, i.e., from in-gel digestion with trypsin, which specifically digests 
protein in lysine and arginine residues. The combination of peptides with a specific ion m/z ratio is 
unique to each protein and depends only on their amino acid sequence and post-translational 
modifications of these; so, this is called protein finger printing. The study may simply be qualitative, 
i.e., determine which peptides and, therefore, proteins are or are not present in the sample, or 
quantitative, to determine their relative abundance between the conditions under study. Many diseases 
are not due to the presence or absence of a specific protein or group of proteins, but to changes in the 
abundance; in this case, it is necessary, as in most cases, to perform a differential metabolic or 
chemical labeling of the samples. Once differentially labeled, samples are mixed, and thereafter, it 
becomes a single process in order to reduce experimental variability and bias, assuming, of course, that 
a precise quantification of the total amount of protein in the different samples has been done previously. 
In a second discovery phase, techniques, such as the difference in-gel electrophoresis (DIGE) [48],  
a variant of the two-dimensional electrophoresis in which the proteins are labeled with a fluorophore, 
the isobaric tags for relative and absolute quantification (iTRAQ) or stable isotope labeling by/with 
amino acids in cell culture (SILAC) are used for relative quantification. The analysis is performed on a 
selected number of samples (in many cases working with sets or pools of samples) and generates a 
panel of several tens of proteins or peptides modulated between the different conditions under study 
and, therefore, to be candidates for potential targets, such as a possible drug treatment. Among the 
most popular platforms used in this phase, we find the linear trap quadrupole (LTQ)-orbitrap and the 
MALDI-TOF/TOF or LC-MALDI-TOF/TOF when combined with an off-line chromatographic 
system. At a later stage of verification, the linear trap quadrupole coupled to Fourier transform ion 
cyclotron resonance (LTQ-FT) or triple quadrupole-ion trap (QqQ-trap) platforms are used, allowing 
direct absolute quantification of a specific candidate in a large number of individual samples, which is 
Proteomes 2014, 2 58 
 
known as multiple or selected reaction monitoring or assays (MRM and SRM, respectively). This 
involves the selection of representative peptides of the candidate that must meet certain characteristics 
and also the synthesis of isotope-labeled versions of that peptides that are spiked in the sample in a 
known amount, enabling absolute quantification of the protein [49].  
In any case, the raw data generated in the analysis of any of the phases are reflected in the mass 
spectra and fragmentation of peptides, which is a dimensional graphical representation of the different 
intensities of detected ions against their m/z ratio. These data are processed and interpreted by search 
engines, equipped with powerful software, using complicated algorithms that integrate the raw data 
with existing protein databases at different sequence repositories (Uniprot, Nextprot, NCBI), allowing 
the identification and, if appropriate, quantification of the proteins present in the samples analyzed. 
The proteomic approach generates informative data on the expression and post-translational 
modifications of proteins that are useful to assess the true potential of MSCs in regenerative medicine. 
No matter which technologies are used, proteomic analysis is always a challenge, because the 
proteome is extremely diverse [50], changes with time and is highly sensitive to pre-analytical 
conditions (Figure 1).  
Figure 1. Workflows used in MSC proteomic analysis. Quantitative methods are indicated 
in red. SCX, strong cation exchange; IMAC, immobilized metal ion affinity chromatography; 
iTRAQ, isobaric tags for relative and absolute quantification.  
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3. Characterization of Mesenchymal Stem Cells  
To date, 2DE gel analysis has been the most used proteomic approach for determining cell surface 
markers of MSCs [51]. The goal is to compare cells from different origins, to follow their 
differentiation and to ultimately define a specific MSC proteomic signature. One important initial task 
is the optimization of 2DE protocols, so that they are robust enough to be used in a multisite project. 
Provansal et al. detailed several thorough protocols that can be used for MSCs in culture [50]. 
Salasznyk et al. [10] identified markers for two cell populations, analyzed the expression of human 
MSC proteins and compared them to those of human osteoblasts using 2D-LC-MS/MS. Among the 
755 different proteins identified in both cell populations, two sets of proteins, 247 found only in 
human MSCs and 158 in human osteoblast cells, were identified. Substantial differences in clusters of 
proteins responsible for calcium-based signaling and cell adhesion were found between the two cell types.  
Feldmann et al. [11] achieved protein identification using MALDI-TOF-MS and gel-matching with 
previously identified databases in their characterization of MSCs from umbilical cord blood after 2DE. 
Roughly 205 molecules were identified representing 145 different proteins and 60 isoforms or post-
translational modifications. The identified proteins could be grouped into several functional categories, 
including metabolism, folding, cytoskeleton, transcription, signal transduction, protein degradation, 
detoxification, vesicle/protein transport, cell cycle regulation, apoptosis and calcium homeostasis.  
Roubelakis et al. [12], using 2DE and the MALDI-TOF-MS approach, have generated, for the first 
time, a protein map of cultured amniotic fluid MSCs by identifying 261 proteins. They directly 
compared the amniotic fluid MSC protein map with that of cultured MSCs from bone marrow and 
found that the functional pattern of the identified proteins from both sources was similar. However, 
cultured MSCs from amniotic fluid displayed a number of unique proteins related to proliferation and 
a primitive phenotype, which may be attributable to the distinct features of the two MSC types. 
Protein profiling of MSC clonal populations was conducted by 2D-LC-MALDI-MS by  
Mareddy et al. [13]. A total of 83 proteins was identified with high confidence, of which 11 showed 
differential expressions between subpopulations, including cytoskeletal and structural proteins, calcium 
binding proteins, cytokinetic proteins and members of the intermediate filament family. This study 
generated a proteome reference map of bone marrow MSCs from the clonal populations, which will be 
valuable to better understand the underlying mechanism of MSC self-renewal and differentiation. 
Li et al. [14], using 2DE and combined MS and MS/MS analysis, identified six differentially 
expressed proteins among MSC samples derived from bone marrow, umbilical cord and placenta, with 
five of them known to be involved in cell migration as either migration enhancing or inhibiting 
proteins. Consistent with their migration capacity, the levels of migration enhancing proteins, 
including cathepsin B, cathepsin D and prohibitin, were significantly lower in MSCs from umbilical 
cord when compared with those MSCs from bone marrow and MSCs from placenta. A higher 
expression for migration inhibiting proteins, including plasminogen activator inhibitor-1 (PAI-1) and 
manganese superoxide dismutase, was found in MSCs from umbilical cord. They also showed that the 
overexpression of PAI-1 impaired the migration capacity for bone marrow and placenta MSCs, while 
silencing of PAI-1 enhanced the migration capacity of umbilical cord MSCs. Their study indicated that 
migration-related proteins are pivotal in the chain of events governing the migration capacity of MSCs. 
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Jaishankar et al. [15] reported a nuclear proteomic analysis of human embryonic and bone  
marrow-derived MSCs. Their proteomic screen highlighted a five-fold difference in the expression of 
Reptin52. They showed, using 2D-DIGE, that Reptin52 is more abundantly expressed in human 
embryonic stem cells than human MSCs. Moreover, they observed differential expression of Pontin52 
and beta-catenin-proteins known to interact with Reptin52, known regulators of beta-catenin, further 
supporting a role for Wnt signaling in stem cell self-renewal and proliferation. 
The expression of a specific set of cell surface cluster differentiation (CD) markers, (CD13, CD29, 
CD44, CD73, CD90, CD105 and CD166) and the absence of hematopoietic stem cell markers (CD34, 
CD45, CD117 [52], HLA class I and HLA-DR antigens [16,17]) strongly support the characterization 
of MSCs using 2DE-PMF. In this regard, it is worth noting that different groups reach similar 
conclusions using different proteomic platforms. 
Mindaye et al. [18] achieved the proteomic analysis of membrane proteins, which is challenging 
and notably underrepresented in proteomic studies, due to the difficulty in the extraction and isolation 
of lipophilic proteins embedded in lipidic layers. They introduced a new approach, including high 
pressure-assisted membrane protein extraction, protein fractionation by gel-eluted liquid fraction 
entrapment electrophoresis [18] and the combined use of liquid chromatography MALDI and ESI 
tandem mass spectrometry. This report presented the first comprehensive proteomic analysis of the 
membrane proteome of undifferentiated and culture-expanded human MSCs from bone marrow 
obtained from different human donors. This new workflow approach enabled them to identify at least 
two-fold more membrane proteins compared to previous published works. A total of 84 cell surface 
CDs were identified, including 14 newly-identified CDs.  
From these works, we can conclude that cellular compartment pre-fractionation drives to a better 
characterization of the stem cell populations, which may be defined in the near future by their 
proteomic profile regardless of their origin, age or stage.  
4. Ex Vivo Cultivation of Mesenchymal Stem Cells  
MSCs hold great promise for cell-based therapeutic use, because of their multipotency and the 
existence of simple methods for in vitro expansion. However, during in vitro expansion, MSCs will 
age and lose their multipotency and proliferation capability. Several studies have provided evidence 
that homogeneous MSCs preparations can be reproducibly isolated under standardized conditions; 
however, culture conditions exert a major impact on the transcriptome, proteome and cellular 
organization of MSCs. Sun et al. [19] used 2DE-MALDI-TOF-MS to perform an analysis during the 
serial subculture of human MSCs. The expression of 12 polypeptides was consistently differentially 
regulated (eight upregulated and four downregulated) during serial subculture until the seventh 
passage. The profile changes were concentrated on proteins related to cell cycle, cell morphology and 
cell proliferation. The data indicated that MSCs underwent morphological changes and a decline in 
proliferation over the course of serial cultivation. Of the differentially regulated proteins, cytoskeletal 
components, including annexin A1 and A2, were upregulated, whereas metabolic, synthetic and 
degradation pathway-related proteins, such as T-complex protein 1 alpha and T-complex protein 1 
gamma, were downregulated during the serial subculture of the isolated human MSCs. Wagner et al. [20] 
using 2DE, also identified 136 protein spots from MALDI-TOF-MS corresponding to the differential 
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protein expression of two human bone marrow populations cultured in two different conditions. 
Proteins involved in metabolism were more highly expressed in low glucose media, whereas proteins 
involved in development, morphogenesis, extracellular matrix and differentiation were more highly 
expressed in a commercial medium.  
Lazzarotto-Silva et al. [21] compared and analyzed MSCs from human bone marrow at different 
culture passages using 2DE-MALDI-TOF-MS/MS and observed similar results in all cultures at  
all passages, suggesting a high degree of similarity among them. The same result was found by  
Binato et al. [22] after image analysis demonstrated that MSCs would have similar protein expression 
patterns at the first passage. These results suggested that the protein profile of human MSC cultures 
derived from different passages and different donors were equivalent. However, changes in the proteomic 
profile of different tissue-derived MSCs during passages in culture have been evaluated using  
surface enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS) by  
Capra et al. [23]. This group evaluated the presence of stable molecular markers in adipose tissue-derived 
MSCs and found changes in the proteomic phenotype following prolonged in vitro culture. The protein 
with the greatest change in expression during cell culture was identified as calcyclin. 
Lee et al. [24] used 2DE coupled to MS to identify differentially expressed proteins at the cell 
membrane level in MSCs growing in basic fibroblast growth factor (bFGF) containing medium; a total 
of 15 differentially expressed proteins were identified, of which nine of them were upregulated and six 
downregulated. The expression level of three actin-related proteins, F-actin-capping protein subunit 
alpha-1, actin-related protein 2/3 complex subunit 2 and myosin regulatory light chain 2, was 
confirmed by complementary analysis. The results indicated that the expression levels of these there 
actin-related proteins were important to the bFGF-induced morphological change of MSCs. 
Madeira et al. [25] studied the molecular mechanisms underlying cellular senescence resulting from 
extended ex vivo cultivation of bone marrow MSCs; they used 2DE-MALDI-MS to demonstrate 
significant evidence of culture-induced senescence. Proteins involved in cellular structure, the 
structure of the cytoskeleton, folding and stress response were less abundant in cells with advanced 
senescence, while proteins involved in energy metabolism, cell cycle regulation, aging and apoptosis 
were more abundant.  
Several studies have reported that caloric restriction increases the proliferation of MSCs and 
decreases apoptosis. Kim et al. [26] examined the effect of low glucose on human bone marrow MSC 
proliferation compared with that under normal glucose conditions to learn if calorie restrictions modify 
the proteomic profile of MSCs in culture. 2DE was utilized, and the results found that calorie 
restriction does not have a significant effect on cell proliferation, reactive oxygen species generation, 
glucose consumption, population doublings and adipogenic differentiation of MSCs. However, they 
identified three upregulated proteins and seven downregulated proteins. These results indicate that 
calorie restriction induced differentially expressed proteins, which may provide further information on 
the aging and differentiation of stem cells. 
A study by Kuboki et al. [27] focused on the mechanotransduction of MSCs in response to matrix 
elasticity. Proteomic profiles of MSCs cultured on tissue culture plastic and soft and stiff matrices 
were determined using DIGE. The results indicated abundance and organization changes in 
cytoskeletal proteins, as well as differential regulation of important signaling-related proteins,  
stress-responsive proteins and also proteins involved in collagen synthesis. The expressions of major 
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cytoskeletal proteins, including actin, tubulin and vimentin, of cells cultured on the gels were 
remarkably changed. Significant downregulation of α-tubulin and β-actin was observed on gel samples 
in comparison to the rigid tissue culture plates. The abundance of expression of vimentin appeared to 
be highest in MSCs cultured on hard gels. These results suggest that the substrate stiffness 
significantly affects the expression levels of the cytoskeletal proteins of MSCs, with implications for 
cellular integrity. 
The proteomic studies done on cultivated MSCs show the high plasticity of these cells, which are 
able to regulate the expression of proteins related to the generation of energy, oxidative stress, cell 
cycle and apoptosis in order to adapt to the factors and conditions of culture. Furthermore, the 
importance of the support used for the culture should be mentioned, since this affects the expression 
of, mainly, proteins related to cytoskeleton structure and cell attachment. 
5. The Mesenchymal Stem Cell Differentiation Process 
Proteomic techniques help to study changes in the human MSC signaling transduction network 
during early differentiation lineage commitment. Several works have demonstrated the value of proteomic 
tools for studying stem cell differentiation and elucidating the underlying molecular mechanisms. 
Wang et al. [28] used ESI-MS/MS to identify proteins in 2DE from human bone marrow MSCs 
cultured with transforming growth factor-β (TGF-β). They generated a proteome reference map of 
MSCs, and they identified approximately 30 proteins with an increase or decrease in the expression or 
phosphorylation in response to TGF-β. The proteins regulated by TGF-β included cytoskeletal 
proteins, matrix synthesis proteins, membrane proteins, metabolic enzymes and others. TGF-β 
increased the expression of smooth muscle alpha-actin and decreased the expression of gelsolin. 
Overexpression of gelsolin inhibited TGF-β-induced assembly of smooth muscle alpha-actin. On the 
other hand, reduction of gelsolin expression enhanced the assembly of alpha-actin and actin filaments 
without significantly affecting alpha-actin expression. These results suggest that TGF-β coordinates 
the increase of alpha-actin and the decrease of gelsolin to promote MSC differentiation. 
Foster et al. [29] used LC coupled MS/MS to characterize changes in the expression of membrane 
protein markers before and after short-term induction of osteoblast differentiation in a cell model of 
human MSCs. They identified 463 unique proteins with extremely high confidence, including all 
known markers of human MSCs, such as CD71, CD105, CD166 and CD44, among 148 integral 
membrane or membrane-anchored proteins and 159 membrane-associated proteins. Twenty-nine 
integrins and cell adhesion molecules, 20 receptors and 18 Ras-related small GTPases were also 
identified. Upon osteoblast differentiation, the expression levels of 83 proteins increased by at least  
two-fold, whereas the levels of another 21 proteins decreased by at least two-fold. 
DIGE-LC coupled with tandem MS analysis of the plasma membrane-containing fraction from 
bone marrow MSCs differentiated towards adipocytes allowed Jeong et al. [30] to identify 707 
proteins, approximately half of which could be identified as membrane-related proteins. Of particular 
interest was a subset of ectodomain-containing membrane-bound proteins, which encompasses most 
known surface markers for MSCs, but also contains a multitude of solute carriers and ATPases. Upon 
adipogenic differentiation, this proteomic profile was amended to include several proteins involved in 
lipid metabolism and trafficking, at the expense of, most noticeably, ectoenzymes. 
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Zhang et al. [31] analyzed protein expression profiles of undifferentiated, as well as osteogenic-
induced MSCs, using 2DE-MALDI-TOF-MS to investigate the early gene expression in osteoblast 
differentiation. They generated proteome maps of undifferentiated human MSCs and osteogenic-induced 
human MSCs on day 3 and day 7. One-hundred two spots with at least two-fold changes in expression 
and 52 differently expressed proteins were successfully identified. These proteins were classified into 
more than seven functional categories: metabolism, signal transduction, transcription, calcium-binding 
protein, protein degradation, protein folding, and others. 
Kim et al. [32] focused on proteins that were differentially expressed during osteogenic 
differentiation of MSCs from umbilical cord blood. They analyzed the protein expression inherent to 
osteogenic differentiation with 2DE-ESI-Q-TOF. Eleven differentially expressed spots were observed 
between the two groups, before and after differentiation; four proteins were found to be involved in the 
osteogenic process for the first time: PGAM1, VBP1, hsp27 and β-actin. β-actin might also prove 
useful as a cytosolic biomarker protein for osteogenesis and could be employed in the quality control 
of osteoblasts for cell-therapy applications. 
Proteomic analysis of human MSCs derived from adipose tissue undergoing osteoblast differentiation 
was realized by Giusta et al. [33]. Phenotypic modifications were observed during the in vitro 
osteogenic differentiation process using DIGE-MALDI-TOF/TOF-MS/MS towards osteoblast-like 
cells. A total of 51 differentially expressed proteins were identified when comparing the three 
observed conditions; 16 of these proteins were identified, five of which were overexpressed in the 
early stages of osteogenic differentiation. All five, superoxide dismutase, lamin A, filamin, heat shock 
protein-27, cathepsin D and fibulin 1, play a very important role in the formation of osteoprogenitor 
cells. The identification of these proteins opened new ways for their use as biomarkers for the 
detection of cells undergoing osteogenesis.  
Kim et al. [34] realized 2DE-MALDI-TOF-MS to study the direct differentiation of MSC from 
umbilical cord blood towards osteoblasts. They found the 308 spots that were identified during the 
differentiation process. Sixteen of these proteins were identified with a mean OD (optical density) ratio 
>30 and were acting in the extracellular region, cytosol or mitochondria, while 20 of these proteins 
with a mean OD ratio <0.1 had high catalytic activity. These results provide an initial proteomic 
database for umbilical cord blood MSCs differentiation.  
Human MSCs differentiated towards chondrocytic cells with conditioned medium derived from 
porcine notochordal cells in native tissue or in alginate beads, and compared with chondrogenic 
(TGFβ-3) or basal medium, were studied by Purmessur et al. [35]. Dried peptides subjected to  
LC-coupled MS/MS for detection indicated the highest levels of glycosaminoglycan (GAG), as well as  
the upregulation of SOX9 and Collagen II gene expression in MSCs differentiated towards 
chondrocyte cells in medium from porcine notochordal cells. 
Protein phosphorylation plays a critical role in the signaling transduction network during early 
human MSCs osteogenic lineage commitment. Human MSCs cultured in osteogenic induction medium 
were analyzed using LC-coupled MS/MS by Lo et al. [36]. They observed a dramatic loss of the 
protein phosphorylation level after one day of osteogenic induction. Pathway analysis of the resulting 
phosphoproteins revealed a high correlation with cell proliferation and protein synthesis pathways. 
During osteogenic differentiation, differentially expressed phosphoproteins demonstrated the dynamic 
alterations in cytoskeleton at early stages of differentiation.  
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De la Fuente et al. [37] followed protein profile changes during the chondrogenic differentiation 
process of MSCs from umbilical cord stroma using DIGE-MALDI-TOF/TOF-MS/MS. A total of 97 spots 
were modulated during the chondrogenesis process; 54 of these spots were identified as 39 different 
proteins and 15 isoforms. Of the 39 different proteins identified, 15 were downregulated, 21 were 
upregulated and three were up- and down-regulated at different phases of the chondrogenic process.  
Rocha et al. [38] applied the SILAC technique for the quantitative analysis of protein modulation 
during the chondrogenic differentiation process of human MSCs from bone marrow. They could 
identify 622 different proteins by LC-MALDI-TOF/TOF-MS/MS analysis and found 65 proteins 
whose abundance was significantly modulated between day 2 and day 14 of chondrogenesis. 
Fibronectin, gelsolin, vimentin, alpha-ATPase, mitochondrial superoxide dismutase and cyclophilin A 
were increased at day 14 compared to day 2 of chondrogenic induction, thus being markers of the 
enhanced extracellular matrix synthesis, cell adhesion, metabolism and response to stress processes 
that take place in the early steps of chondrogenesis.  
Herencia et al. [39] evaluated the role of Wnt/β-catenin activation during human MSC 
differentiation into hepatocytes. The differentiation to hepatocytes was achieved using two different 
conditioned media. Comparison of both differentiation protocols by DIGE revealed the differential 
expression of 11 proteins with altered expression in hepatocellular carcinoma. In one of these 
protocols, β-catenin nuclear translocation and the upregulation of genes related to the Wnt/β-catenin 
pathway, such as Lrp5 and Fzd3, as well as the oncogenes, c-myc and p53, were observed. In the other 
protocol, Wnt/β-catenin was inactivated. Hepatocytes with nuclear translocation of β-catenin also had 
abnormal cellular proliferation and expressed membrane proteins involved in hepatocellular 
carcinoma, metastatic behavior and cancer stem cells. Further, these cells had also an increased  
auto-renewal capability, as shown in a spheroid formation assay. Cathepsin B and D, adenine 
phosphoribosyltransferase, triosephosphate isomerase, inorganic pyrophosphatase, peptidyl-prolyl  
cis-trans isomerase A or lactate dehydrogenase β-chain were upregulated only with the protocol 
associated with Wnt signaling activation, while other proteins involved in tumor suppression, such as 
transgelin or tropomyosin β-chain, were downregulated in this protocol.  
Alves et al. [40] used SILAC to study the effect of activin A on the osteogenic differentiation of 
MSCs from bone marrow. They found 104 proteins changed more than 1.5-fold following activin A 
treatment. More than half of these proteins, 74 proteins, were downregulated by activin A, while only 
30 proteins were upregulated. They observed changes in the expression of collagen XII, osteonectin 
and several cytoskeleton-binding proteins. Moreover, in osteoblasts differentiated from MSCs, matrix 
vesicle production was deficient, containing a very low expression of annexin proteins. 
Proteomics provides, therefore, very valuable information in directed differentiation studies of 
MSCs. All the works above have generated new knowledge on the metabolic pathways modulated 
during the differentiation, thus permitting a better understanding of the processes. The precision and 
accuracy of the techniques allow the detection of very subtle changes in the expression of proteins or 
in their phosphorylation state. It is also remarkable that proteomics has permitted the detection in 
cultured MSCs of the activation of oncogenic factors by certain culture conditions, an undesirable 
process when it comes to the use of these cells in therapeutic treatment. 
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6. Cellular Therapy with Mesenchymal Stem Cell 
MSCs have emerged as a promising tool for treating degenerative or incurable diseases. Proteomic 
techniques provide a comprehensive basis for understanding the potential effect of MSCs on tissue 
repair and regeneration. Knowledge of the molecular mechanisms governing the different adult lineages 
differentiation process is critical to the development of therapeutic applications for human diseases. 
Seshi B et al. [41] reported a 2D-DIGE protocol in which complex protein samples from normal 
and leukemic human bone marrow mesenchymal progenitor cells were used as model samples for a 
combination of liquid-phase IEF with DIGE. Using liquid-phase IEF, the normal and leukemic cells 
were pre-fractionated into five sub-proteomes after multiplexing, but prior to DIGE. This analysis mapped 
protein identities to 128 mesenchymal progenitor cell proteins with at least one unique peptide match 
at >95% confidence. Of these proteins, 72 (56%) were expressed more than 1.25-fold higher or lower 
in leukemic cells compared with normal cells (p < 0.05). These data were used to infer gene ontology 
biological processes that may be altered in leukemic bone marrow mesenchymal progenitor cells. 
The first proteomic analysis of human MSCs after exposure to shear stress was realized by Yi et al. [42] 
using 2DE and MALDI-TOF-MS. Overall, 32 protein spots were identified with high confidence.  
Thirteen of these proteins were found to be consistently regulated by over two-fold after 3 dyn/cm
2
 
shear stress treatment for six hours; 10 were upregulated and three downregulated.  
DIGE-MALDI-TOF/TOF was utilized by Zhuang et al. [43] to analyze the differential proteome of 
bone marrow-derived MSCs from adolescent idiopathic scoliosis. A total of 41 significantly altered 
protein spots were detected, of which 34 were identified, representing 25 distinct gene products. 
Among these proteins, five related to bone growth and development, including pyruvate kinase M2, 
annexin A2, heat shock 27 kDa protein, γ-actin, and β-actin, were found to be dysregulated. At the 
protein level, the results supported the previous hypothesis that the decreased osteogenic 
differentiation ability of MSCs is one of the mechanisms leading to osteopenia in adolescent  
idiopathic scoliosis. 
Recent studies have shown that microvesicles from MSCs contribute to the recovery of damaged 
tissues in animal disease models. Kim et al. [44] profiled the MSC microvesicles proteome from bone 
marrow to investigate its therapeutic effects. Seven-hundred thirty proteins were identified by LC 
coupled MS/MS analysis of MSC microvesicles separated by SDS-PAGE. This proteome included 
five positive and two variable known markers of MSCs, but no negative markers. In addition, 43 
surface receptors and signaling molecules controlling self-renewal and differentiation of MSCs were 
identified. This analysis showed that cellular processes represented by the MSC microvesicle proteins 
include cell proliferation, adhesion, migration and morphogenesis. The integration of the self-renewal of 
MSCs and differentiation-related genes that can be associated with the therapeutic effects of MSC 
microvesicles includes: surface receptors; signaling molecules (CDC42 and VAV2; cell adhesion); and 
MSC-associated antigens (CD109, CD151, CD248 and CD276). These proteomes provide a 
comprehensive basis for understanding their potential effect on MSC microvesicle tissue repair  
and regeneration. 
Dynamic changes in the phosphoproteomic profiles of human MSCs during osteogenic differentiation 
and revealed potential candidates mediating the osteogenic commitment of human MSCs shown by 
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liquid chromatography tandem mass spectrometry [36] may shed light on the development of new 
therapeutic targets for metabolic bone diseases, such as osteoporosis and osteomalacia. 
Han S et al. [45] studied differential proteins expressed in the MSCs of patients with degenerative 
scoliosis. They compared MSCs from patients with degenerative scoliosis and patients with lumbar 
spinal stenosis. The MSC samples were analyzed by DIGE-MALDI-TOF-MS to find the differential 
proteins. They found 115 spots that were expressed differently in the MSCs of degenerative scoliosis 
patient; 44 proteins were identified. Of these proteins, PIAS2, NDUFA2 and TRIM 68 were  
upregulated in degenerative scoliosis. This information from this proteomics analysis will be useful in 
understanding the pathophysiology of degenerative scoliosis and opens further lines of investigation on 
the functional pathway, the specificity and the mechanism of action of these proteins.  
Proteomic profiling has provided a variety of novel molecular procedures that can form the basis 
for more in-depth investigations into the effects of shear stress in vitro human MSCs proliferation, 
differentiation and apoptosis; this may, in turn, significantly influence applications in stem cell therapy 
and tissue regeneration. 
7. Outlook and Perspectives 
Liquid chromatography-multiple reaction monitoring mass spectrometry of peptides using stable 
isotope dilution [53] provides a powerful tool for targeted protein quantification. However, the high 
cost of labeled peptide standards for stable isotope dilution (SID) is an obstacle to multiple reaction 
monitoring studies. Zhang et al. [53] compared SID to a labeled reference peptide (LRP) method, 
which uses a single labeled peptide as a reference standard for all measured peptides, and a label-free 
(LF) approach, in which quantification is based on the analysis of un-normalized peak areas for 
detected MRM transitions. They concluded that the LRP and LF methods provide cost-effective 
alternatives to SID for many quantitative liquid chromatography-multiple reaction monitoring mass 
spectrometry applications. These procedures have not yet been applied to study the application of 
MSCs to cell therapy, but offer this opportunity. Proteomic differential displays could help to increase 
the cell therapies with MSCs through specific adjustments based on these displays. 
Promising techniques need special mention here. Matrix assisted laser desorption ionization mass 
spectrometry imaging (MALDI-MSI) and laser micro-dissection are currently under expansion and 
development. The MALDI-MSI combines high resolution power and the ability to monitor a large 
number of proteins in a single analysis feature of the mass spectrometry and has the advantage of 
being able to apply histomorphologic techniques, including providing visual information about the 
spatial distribution of analytes. The approach is as simple as a laser ―sweep‖ with a given spatial 
resolution, 50 microns or less, of a tissue, cut with histological techniques for mass spectrometry, to 
determine the intensity at each pixel of a certain range of m/z. In practice, this involves making a  
two-dimensional map of the distribution of ions (peptides, lipids, sugars) in a histological section. 
Although, at first, it was successful only in soft tissues (brain, kidney, lung, etc.) [54,55], investigators 
have recently begun to utilize it successfully in tissues, such as cartilage [56]. The laser capture  
micro-dissection (LCM) technique identifies LCM regions corresponding to individual cells or groups 
of cells in tissue sections, using a laser coupled to a microscope. The resulting sections are deposited in 
micro-tubes for analysis, in this case, an extraction of proteins that can be further examined with 
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differential labeling to, for example, determine the differential proteome of cells or groups of adjacent 
cells in the same tissue [57]. This technique opens possibilities to study small groups of MSCs 
undergoing cell division after differentiation. 
8. Conclusions 
To summarize, applied mass spectrometry proteomics has enabled a breakthrough in resolving the 
power and speed of analysis. Few techniques have proven valid for detection, analysis and 
quantification, in a single experiment, of many analytes; mass spectrometry is one of them. Thus far, 
2D-based proteomic strategies have been primarily used to characterize MSCs. In the future, it will be 
essential to use gel-free-based strategies to delve deeper into the characteristic proteomes of different 
MSC populations. While increasingly specific and sensitive equipment is launched on the market 
every year, clinical validation by other, even more sensitive techniques, such as RT-PCR and 
immunoassays, is still needed. 
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